Detailed Findings

Dealmaking in 2025

0%

IPOs make a comeback in dealmaking activity

Is the IPO market coming back? 20% expect equity raising and IPOs to dominate transactional activity next year, versus just 6% who said the same last year – and up from the lows of 1% who had confidence in this area of the market in 2022. In fact, this makes 2024 the most bullish outlook for IPOs since we began this survey in 2018, which bodes well for companies looking to come to market. There was a notable uptick across Private Equity, Institutional Investors and Corporates in particular. 

Expectations for Corporate-led M&A have waned versus last year, but are still expected to dominate (49% this year versus 60% last year). Private Equity, Institutional Investors, and the Corporates themselves, are aligned in this dropping down the to-do list. 

Expectations for Private Equity-led M&A remain consistent with the last few years (17% this year versus 16% and 15% in 2023 and 2022 respectively) – and down from the higher 24% in 2021. Debt refinancing was very low down the agenda (3%), alongside restructurings (3%). 

What transactional activity do you expect to dominate the Healthcare sector in 2025?

What transactional activity do you expect to dominate the Healthcare sector in 2025?
All (2022)All (2023)All (2024)Institutional InvestorPrivate Equity InvestorHealthcare Corporate Representative
M&A led by Corporates546049583949
M&A led by Private Equity15161772518
Equity Financing, including IPOs1620231821
Debt Refinancing8732102
Restructuring003203
Do not know445525
Other100000
None will dominate554173

IMPORTANT: You must read the following before reading, accessing or making any other use of this publication. In accessing this publication, you agree to be bound by the following terms and conditions. This document is being furnished for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to purchase any security or other financial instrument or product. It is not intended to form the basis of any investment decision. Jefferies International Limited and its affiliates (together “Jefferies”) makes no representation as to the accuracy or completeness of the information contained herein or any other information, whether written or oral, made available. Jefferies disclaims all and any liability whatsoever, whether arising in tort, contract or otherwise, for the contents of this publication. You acknowledge that Jefferies does not owe you or any other person or entity, any fiduciary or similar duty as a result of the publication of this report, and Jefferies is not providing any advice, including with respect to legal, tax, accounting, investment or regulatory matters, in any jurisdiction.